Song, N., Qu, J., Chen, Y., Li, D., Qu, X. (2026). Camrelizumab plus rivoceranib as first-line maintenance therapy after camrelizumab-chemo induction in advanced esophageal squamous cell carcinoma: A prospective, single-arm, phase II clinical trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.19_suppl.tps158